JNJ-42165279 | CAS# 1346528-50-4 | FAAH inhibitor

MedKoo Cat#: 522477 | Name: JNJ-42165279

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JNJ-42165279 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. JNJ-42165279 covalently inactivates the FAAH enzyme, but is highly selective with regard to other enzymes, ion channels, transporters, and receptors. JNJ-42165279 exhibited excellent ADME and pharmacodynamic properties as evidenced by its ability to block FAAH in the brain and periphery of rats and thereby cause an elevation of the concentrations of anandamide (AEA), oleoylethanolamide (OEA), and palmitoyl ethanolamide (PEA). JNJ-42165279 was also efficacious in the spinal nerve ligation (SNL) model of neuropathic pain. JNJ-42165279 is currently under clinical trials.

Chemical Structure

JNJ-42165279

CAS#1346528-50-4 (free base)

Theoretical Analysis

MedKoo Cat#: 522477

Name: JNJ-42165279

CAS#: 1346528-50-4 (free base)

Chemical Formula: C18H17ClF2N4O3

Exact Mass: 410.0957

Molecular Weight: 410.81

Elemental Analysis: C, 52.63; H, 4.17; Cl, 8.63; F, 9.25; N, 13.64; O, 11.68

Price and Availability

Size	Price	Availability
100mg	USD 1,350.00	2 Weeks
200mg	USD 2,250.00	2 Weeks
500mg	USD 2,950.00	2 Weeks
1g	USD 4,950.00	2 Weeks
2g	USD 7,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1346528-50-4 (free base) 1346528-52-6 (mono HCl salt) 1346528-51-5 (2HCl salt)

Synonym

JNJ-42165279; JNJ 42165279; JNJ42165279.

IUPAC/Chemical Name

N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxamide

InChi Key

YWGYNGCRVZLMCS-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)

SMILES Code

O=C(N1CCN(CC2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=C(Cl)C=CN=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

JNJ-42165279 is a FAAH inhibitor with IC50 of 70 ± 8 nM and 313 ± 28 nM for hFAAH and rFAAH, respectively.

In vitro activity:

BIA 10‐2474, PF‐04457845 and JNJ‐42165279 concentration‐dependently inhibited human recombinant fatty acid amide hydrolase in COS‐human fatty acid amide hydrolase cells at all tested pre‐incubation periods (IC50 values are in Table 2). The IC50 values for PF‐04457845 were similar to those observed in vitro, in contrast to BIA 10‐2474 and JNJ‐42165279, which inhibited more potently fatty acid amide hydrolase in cells than in vitro. Reference: Br J Pharmacol. 2020 May;177(9):2123-2142. doi: 10.1111/bph.14973. https://pubmed.ncbi.nlm.nih.gov/31901141/

In vivo activity:

JNJ-42165279 exhibited excellent ADME and pharmacodynamic properties as evidenced by its ability to block FAAH in the brain and periphery of rats and thereby cause an elevation of the concentrations of anandamide (AEA), oleoyl ethanolamide (OEA), and palmitoyl ethanolamide (PEA). Reference: ACS Med Chem Lett. 2015 Nov 2;6(12):1204-8. https://pubmed.ncbi.nlm.nih.gov/26713105/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	73.03
	DMSO	65.0	158.23
	Ethanol	30.0	73.03

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 410.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bonifácio MJ, Sousa F, Aires C, Loureiro AI, Fernandes-Lopes C, Pires NM, Palma PN, Moser P, Soares-da-Silva P. Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474. Br J Pharmacol. 2020 May;177(9):2123-2142. doi: 10.1111/bph.14973. Epub 2020 Feb 12. PMID: 31901141; PMCID: PMC7161550. 2. Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS Med Chem Lett. 2015 Nov 2;6(12):1204-8. doi: 10.1021/acsmedchemlett.5b00353. PMID: 26713105; PMCID: PMC4677372.

In vitro protocol:

In vivo protocol:

John M. Keith,* William M. Jones, Mark Tichenor, Jing Liu, Mark Seierstad, James A. Palmer, Michael Webb, Mark Karbarz, Brian P. Scott, Sandy J. Wilson, Lin Luo, Michelle L. Wennerholm, Leon Chang, Michele Rizzolio, Raymond Rynberg, Sandra R. Chaplan, and J. Guy Breitenbucher. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279, ACS Med. Chem. Lett. Articles ASAP (As Soon As Publishable), Publication Date (Web): November 2, 2015 (Letter), DOI: 10.1021/acsmedchemlett.5b00353